Analysts See $-0.66 EPS for Karyopharm Therapeutics Inc. (KPTI)

February 23, 2018 - By Henry Gaston

 Analysts See $ 0.66 EPS for Karyopharm Therapeutics Inc. (KPTI)
Investors sentiment increased to 2.5 in Q3 2017. Its up 0.94, from 1.56 in 2017Q2. It improved, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported.
Tudor Investment Corp Et Al reported 18,075 shares. Nationwide Fund Advsr accumulated 105,664 shares or 0% of the stock. Sg Americas Securities Ltd Llc has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Tiaa Cref Investment Mgmt Ltd Llc owns 90,677 shares or 0% of their US portfolio. Art Advsr Ltd Liability Co stated it has 26,552 shares or 0.01% of all its holdings. New York-based Bancorporation Of Mellon has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Morgan Stanley has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Jacobs Levy Equity Inc invested in 24,600 shares. Barclays Public Ltd reported 7,157 shares. Great West Life Assurance Can stated it has 1,658 shares or 0% of all its holdings. Goldman Sachs Gru Incorporated Inc has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Manufacturers Life Insurance The stated it has 26,084 shares. 54,693 were accumulated by California State Teachers Retirement Systems. Rhumbline Advisers holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 75,207 shares. First Personal Financial Services has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Since August 29, 2017, it had 0 insider buys, and 18 insider sales for $1.31 million activity. The insider Shacham Sharon sold 10,000 shares worth $91,553. On Friday, September 15 Primiano Christopher Brett sold $22,000 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 2,000 shares. $91,553 worth of stock was sold by Kauffman Michael on Monday, December 18.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.66 EPS on March, 15.They anticipate $0.01 EPS change or 1.54 % from last quarter’s $-0.65 EPS. After having $-0.65 EPS previously, Karyopharm Therapeutics Inc.’s analysts see 1.54 % EPS growth. The stock decreased 1.42% or $0.21 during the last trading session, reaching $14.59. About 188,754 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 23, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Buy” rating by MLV on Wednesday, August 12. The firm has “Buy” rating given on Monday, September 11 by Jefferies. The firm has “Outperform” rating given on Friday, May 27 by Raymond James. The firm has “Buy” rating by Jefferies given on Thursday, October 12. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Thursday, January 11 by H.C. Wainwright. The firm has “Underperform” rating given on Tuesday, March 15 by Bank of America. H.C. Wainwright reinitiated it with “Buy” rating and $23 target in Wednesday, November 15 report. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by H.C. Wainwright on Tuesday, December 12. The firm has “Overweight” rating given on Monday, March 14 by JP Morgan. Canaccord Genuity maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Tuesday, August 8 with “Buy” rating.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $722.69 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

More recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “What’s Next For Karyopharm Therapeutics?” on December 15, 2017. Also Globenewswire.com published the news titled: “Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule …” on February 01, 2018. Globenewswire.com‘s news article titled: “Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment …” with publication date: January 25, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.